Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

NCT07008638 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
TP53

Interventions

DRUG: Bortezomib
DRUG: CPX-351

Sponsor

Masonic Cancer Center, University of Minnesota